Dr. Reddy's Laboratories Ltd. said it had launched Decitabine for Injection in 50 mg strength, a therapeutic equivalent generic version of Dacogen (Decitabine for Injection) in the US market on July 11, following the approval by the US FDA of the company's ANDA for Decitabine for Injection.
As per IMS Health data, the Dacogen brand had sales of around $260 million in the US for the twelve months ended July 2013.
The company said the Decitabine for Injection 50 mg would be available as a single dose vial.
At the BSE, Dr. Reddy's Laboratories shares are currently trading at Rs.2,295.95, down 0.21 percent from the previous close.
For comments and feedback: editorial@rttnews.com